



## **Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018**

February 22, 2018

DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors' section of the Company's website, [www.chimerix.com](http://www.chimerix.com). An archived webcast will be available on the Chimerix website approximately two hours after the event.

### **About Chimerix**

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, [www.chimerix.com](http://www.chimerix.com).

### **CONTACT:**

#### Investor Relations:

Michelle LaSpaluto

919-972-7115

[ir@chimerix.com](mailto:ir@chimerix.com)

or

Will O'Connor

Stern Investor Relations

[Will@sternir.com](mailto:Will@sternir.com)

212-362-1200

#### Media:

Becky Vonsiatsky

W2O Group

[bvonsiatsky@w2ogroup.com](mailto:bvonsiatsky@w2ogroup.com)

413-478-2003



**CHIMERIX**

Source: Chimerix, Inc.